Analyst Reco. LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
7.49 ^USD	+1.35%		+7.31%	-4.34%

05-14	Lifestance Health Group Insider Sold Shares Worth $362,567, According to a Recent SEC Filing	MT
05-09	Transcript : LifeStance Health Group, Inc., Q1 2024 Earnings Call, May 09, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lifestance Health Group Insider Sold Shares Worth $362,567, According to a Recent SEC Filing	05-14	MT
Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating	03-06	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Neutral Rating	03-04	MT
UBS Adjusts LifeStance Health Group Price Target to $9 From $7, Maintains Neutral Rating	02-29	MT
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating	02-29	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $8 From $9, Maintains Neutral Rating	11-22	MT
JPMorgan Adjusts LifeStance Health Group's Price Target to $8 From $10, Maintains Neutral Rating	11-17	MT
UBS Cuts LifeStance Health Group's Price Target to $7 From $10, Keeps Neutral Rating	11-09	MT
Goldman Sachs Adjusts LifeStance Health Group's Price Target to $9 From $8, Keeps Neutral Rating	19/05/23	MT
UBS Adjusts LifeStance Health Price Target to $10 From $7, Maintains Neutral Rating	12/05/23	MT
Morgan Stanley Adjusts Price Target on LifeStance Health to $10 From $8, Maintains Overweight Rating	11/05/23	MT
UBS Adjusts Price Target on LifeStance Health to $7 From $6.50, Maintains Neutral Rating	09/03/23	MT
Morgan Stanley Upgrades LifeStance Health Group to Overweight From Equalweight With $8 Price Target	06/01/23	MT
Goldman Sachs Trims Price Target on LifeStance Health Group to $8 From $9, Maintains Neutral Rating	15/11/22	MT
Cowen Trims Price Target on LifeStance Health Group to $8 From $10, Maintains Outperform Rating	14/11/22	MT
UBS Adjusts LifeStance Health Group Price Target to $6.50 From $7, Maintains Neutral Rating	09/11/22	MT
Jefferies Assumes LifeStance Health at Buy Rating With $7.25 Price Target	07/11/22	MT
Cowen Adjusts Price Target on LifeStance Health Group to $10 From $11, Keeps Outperform Rating	22/08/22	MT
Jefferies Lowers Price Target for LifeStance Health Group to $10 From $15, Maintains Buy Rating	10/08/22	MT
JPMorgan Adjusts Price Target for LifeStance Health Group to $9 From $12, Maintains Neutral Rating	10/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Analyst Reco.

Filters